EU Approves Sanofi and Regeneron's Dupixent for Severe Asthma
07 Maggio 2019 - 3:39PM
Dow Jones News
By Cristina Roca
Sanofi SA (SAN.FR) and Regeneron Pharmaceuticals Inc. (REGN)
said Tuesday that Dupixent has been approved for the treatment of
severe asthma in the European Union.
The two pharmaceutical companies developed the drug jointly,
they said in a press release.
Dupixent is approved in the EU to treat moderate-to-severe
atopic dermatitis in adults, and has now been given approval by the
European Commission to treat severe asthma with type 2 inflammation
in adults and patients 12 years and older.
Write to Cristina Roca at cristina.roca@dowjones.com;
@_cristinaroca
(END) Dow Jones Newswires
May 07, 2019 09:24 ET (13:24 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Grafico Azioni Sanofi (EU:SAN)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Sanofi (EU:SAN)
Storico
Da Apr 2023 a Apr 2024
